Regulatory Approval

A new report reveals a dangerous disconnect: while AI accelerates coding, 95% of CISOs are pressured to ignore the security flaws it creates.

A Canadian upstart is poised to unlock a massive, untreated market by moving glaucoma surgery from the OR to the office. This isn't just a new device; it's a strategic dismantling of a decades-old bottleneck.

Amai Proteins' sweelin® just got a major scientific boost. New clinical data in a top journal proves its metabolic safety, fast-tracking its commercial journey.

A top environmental rating for Musim Mas isn't just an award; it's a look into the future of corporate responsibility where accountability extends to its source.

Tompkins Financial is rebranding, swapping 'Community' for 'Trust.' It's more than a name change—it's a calculated strategy to redefine its market position.

As Uber pushes for laws to limit its crash liability, consumer icon Ralph Nader warns the tech giant is dismantling decades of auto safety progress.

Canada's new 'AI for All' strategy bets billions on sovereign compute and closing its adoption gap. Can this ambitious plan build a uniquely Canadian AI future?

With key regulatory decisions pending in Canada and the US, DIAGNOS's CARA AI platform is set to unlock a multi-billion dollar market for early eye disease detection.

With the approval of its advanced cancer drug Eratrectinib, Vcare PharmaTech challenges global rivals, showcasing China's AI-driven R&D and strategic ambition.

A new pact with Galaxy Digital lets Morgan Stanley's elite clients swap crypto for ETPs. Is this the moment Wall Street fully embraces DeFi, or a risky new frontier?

A new firm offers up to $250k in funded accounts for prediction market traders, a move that could professionalize a booming sector. But can it navigate the complex regulatory field?

BioCardia’s innovative cell therapy for heart failure receives a crucial FDA signal, potentially paving the way for a new treatment paradigm for millions.

Advocacy groups demand a congressional audit, alleging the BLM's sales program creates an unregulated pipeline for slaughtering protected wild horses.

Landmark trial results for Bayer's KERENDIA unlock a vast new market in non-diabetic kidney disease, offering hope to millions and a strategic win for the firm.

Behind the jargon of a financing announcement, GoldHaven Resources is accelerating its high-stakes search for critical minerals across two continents. What does this move signal?

A private startup just achieved a nuclear first in 40 years. This rapid milestone, driven by new policy, signals a new era for energy innovation.

A small insurer's shift into annuities reveals a larger story: how its parent, Brookfield, is re-engineering its empire to dominate the retirement market.

Chinese vaccine maker Zhengye Biotechnology has 180 days to save its Nasdaq listing. But the sub-$1 stock price is just a symptom of deeper financial decay.

An Austin law firm's national ranking reveals a powerful new model for success, blending elite talent with operational agility and deep diversity.

A French firm is using a special economic zone to bypass China's tough regulations. Is its scarless vein treatment a medical breakthrough or a brilliant market hack?